Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ALK201 injection combined with ivonescimab in advanced or metastatic squamous non-small cell lung cancer
CTR20262935Phase 2Active
- Sponsor
- Allink Biotherapeutics
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ALK201, ivonescimab in Pulmonary squamous cell carcinoma, sponsored by Allink Biotherapeutics. Started Jul 2026; status: active.
02
Drugs
ALK201ivonescimab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on CTR20262935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262935.